Close Menu

NewGene

NEW YORK (GenomeWeb News) – Sequenom today said that it has launched a certified service program for its MassArray System and has named the first laboratory participants.

NewGene has launched a sequencing-based test on Roche's 454 GS FLX for Noonan syndrome and other related disorders.

NewGene's hereditary breast cancer test

NewGene is initially targeting the UK market and patients with an increased hereditary risk for breast cancer for its pyrosequencing-based assay.

The UK firm will provide services for NimbleGen Sequence Capture Arrays with sequencing on Roche 454's Genome Sequencer FLX System.

The company expects to use Roche's 454 technology to offer full-gene sequencing tests at a lower cost and faster turnaround time than existing providers using Sanger sequencing.

Paired Ends: Aug 4, 2009

Premium

David Huntley, Ann Curtis, Jonathan Robinson, Jonathan Coxhead, David Allison, John Burn, Michael Wright, Kary Mullis

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.